SG11201610221WA - Peptides as oxytocin agonists - Google Patents

Peptides as oxytocin agonists

Info

Publication number
SG11201610221WA
SG11201610221WA SG11201610221WA SG11201610221WA SG11201610221WA SG 11201610221W A SG11201610221W A SG 11201610221WA SG 11201610221W A SG11201610221W A SG 11201610221WA SG 11201610221W A SG11201610221W A SG 11201610221WA SG 11201610221W A SG11201610221W A SG 11201610221WA
Authority
SG
Singapore
Prior art keywords
peptides
oxytocin agonists
oxytocin
agonists
Prior art date
Application number
SG11201610221WA
Other languages
English (en)
Inventor
Caterina Bissantz
Konrad Bleicher
Kanchan Chakraborty
Christophe Grundschober
Goutam Saha
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG11201610221WA publication Critical patent/SG11201610221WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11201610221WA 2014-06-06 2015-06-03 Peptides as oxytocin agonists SG11201610221WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14171440 2014-06-06
PCT/EP2015/062314 WO2015185584A1 (en) 2014-06-06 2015-06-03 Peptides as oxytocin agonists

Publications (1)

Publication Number Publication Date
SG11201610221WA true SG11201610221WA (en) 2017-01-27

Family

ID=50932985

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201610221WA SG11201610221WA (en) 2014-06-06 2015-06-03 Peptides as oxytocin agonists

Country Status (16)

Country Link
US (1) US20170081368A1 (ko)
EP (1) EP3152225B1 (ko)
JP (1) JP6535688B2 (ko)
KR (1) KR20170004014A (ko)
CN (1) CN106459156A (ko)
AU (1) AU2015270564A1 (ko)
CA (1) CA2950493A1 (ko)
CL (1) CL2016003076A1 (ko)
CR (1) CR20160562A (ko)
EA (1) EA030296B1 (ko)
IL (1) IL248625A0 (ko)
MX (1) MX2016015877A (ko)
PE (1) PE20170427A1 (ko)
PH (1) PH12016502251A1 (ko)
SG (1) SG11201610221WA (ko)
WO (1) WO2015185584A1 (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20240166T1 (hr) 2014-09-19 2024-04-26 Ferring B.V. Postupak liječenja prader-willijevog sindroma
BR112020001832A2 (pt) 2017-08-11 2020-07-28 Ferring B.V. método de produção de uma composição farmacêuti-ca
WO2019032946A1 (en) 2017-08-11 2019-02-14 Ferring B.V. PROCESS FOR PRODUCING OXYTOCIN
TW202031283A (zh) 2018-09-20 2020-09-01 馬克 Ｃ 曼寧 穩定卡貝縮宮素鼻內製劑
US11207373B2 (en) 2018-09-20 2021-12-28 Levo Therapeutics, Inc. Agitation process for preparing a carbetocin drug product
CN113801200B (zh) * 2021-09-28 2023-07-25 浙江湃肽生物有限公司 一种卡贝缩宫素的制备方法
WO2024044633A2 (en) * 2022-08-23 2024-02-29 Seattle Children's Hospital (D/B/A Seattle Children's Research Institute) Oxytocin derivatives and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4483794A (en) * 1983-05-10 1984-11-20 Ceskoslovenska Akademie Ved Analogs of neurohypophysial hormones
KR20070022753A (ko) * 2004-05-26 2007-02-27 화이자 인코포레이티드 인다졸 및 인돌론 유도체 및 이의 약제로서의 용도
FR2875499B1 (fr) * 2004-09-20 2006-10-27 Sanofi Aventis Sa Nouveaux derives pyridiniques d'indolin-2-one, leur preparation et leur application en therapeutique
CN101641013B (zh) * 2007-01-22 2014-07-30 Gtx公司 核受体结合剂
SI2260053T1 (sl) * 2008-03-31 2014-08-29 Ferring Bv Analogi oksitocina
WO2010034656A1 (en) * 2008-09-23 2010-04-01 F. Hoffmann-La Roche Ag Isoxazolo[4,5]pyridin-3-yl-piperazin derivatives useful as modulatorsof dopamine d3 receptors
EP2427458B1 (en) * 2009-05-05 2014-05-07 F.Hoffmann-La Roche Ag Isoxazole-pyridazine derivatives
TWI463990B (zh) * 2009-09-21 2014-12-11 Ferring Bv 催產素受體促進劑
AU2010302945B2 (en) * 2009-10-01 2015-09-24 The University Of Sydney Therapy and prevention of problem drinking
US9585935B2 (en) 2010-07-30 2017-03-07 The Regents Of The University Of California Intranasal oxytocin treatment to improve schizophrenia

Also Published As

Publication number Publication date
JP6535688B2 (ja) 2019-06-26
EA030296B1 (ru) 2018-07-31
CA2950493A1 (en) 2015-12-10
CN106459156A (zh) 2017-02-22
JP2017518313A (ja) 2017-07-06
EP3152225B1 (en) 2018-11-14
MX2016015877A (es) 2017-03-27
EP3152225A1 (en) 2017-04-12
US20170081368A1 (en) 2017-03-23
AU2015270564A1 (en) 2016-11-17
EA201692488A1 (ru) 2017-05-31
CR20160562A (es) 2017-01-06
CL2016003076A1 (es) 2017-08-11
IL248625A0 (en) 2017-01-31
WO2015185584A1 (en) 2015-12-10
PH12016502251A1 (en) 2017-02-06
PE20170427A1 (es) 2017-04-26
KR20170004014A (ko) 2017-01-10

Similar Documents

Publication Publication Date Title
GB201418562D0 (en) Peptides
IL248625A0 (en) Peptides as oxytocin agonists
GB201508337D0 (en) Novel peptides
HK1243106A1 (zh) 唾液富酪蛋白肽
GB201520536D0 (en) Peptides
IL248553A0 (en) Peptides as oxytocin agonists
GB201401877D0 (en) Peptides
GB201520544D0 (en) Peptides
GB201520567D0 (en) Peptides
GB201520541D0 (en) Peptides
GB201520539D0 (en) Peptides
GB201520543D0 (en) Peptides
HK1253316A1 (zh) 肽
GB201503483D0 (en) Novel Antimmicrobial Peptides
GB201520542D0 (en) Peptides
GB201520548D0 (en) Peptides
GB201409536D0 (en) Chemically modifying peptides
GB201420645D0 (en) Peptides
GB201408629D0 (en) Novel peptides
GB201412731D0 (en) Peptides
GB201520534D0 (en) Peptides
GB201520554D0 (en) Peptides
GB201520538D0 (en) Peptides
GB201520537D0 (en) Peptides
GB201520535D0 (en) Peptides